Search bioRxiv⌕ Search

Biology subjects

Politch, J. A.

Publications and source records attributed to Politch, J. A..

2 recordsLinked to original sources

Complement protein concentrations and activity in human cervical mucus

ProblemComplement, a system of over 30 interacting proteins, functions as a critical immune mediator at mucosal surfaces including the intestine, airway, and nasal mucosae, where it orchestrates complement-dependent cytotoxicity (CDC), complement-dependent phagocytosis (CDP), and inflammatory responses. While complement components have been detected at low levels in genital tract fluids, including cervical mucus, the physiologic dynamics of complement in the female reproductive tract remain poorly characterized. Notably, systematic quantification of complement component levels across the menstrual cycle has not been conducted, limiting our understanding of how hormonal fluctuations may influence complement-mediated protection at the vaginal mucosa. Method of studyTen healthy women of reproductive age were recruited to provide paired samples of cervical mucus (CM) and serum (S) during each phase of the menstrual cycle: follicular, ovulatory, and luteal. Samples were analyzed using bead-based multiplex assays to quantify 13 primary complement components. ResultsAll 13 complement proteins tested were detectable in CM and S; C3b/iC3b was the predominant complement component in CM followed by C4 and C3. In contrast, C4 was the dominant component in S followed by C1q and C3. There were significantly higher levels of C2 in CM during the follicular phase of the menstrual cycle vs. the ovulatory phase (1.15{+/-}0.80 vs 0.24{+/-}0.22{micro}g/mL), C4b (0.56{+/-}0.35 vs 0.22{+/-}0.36 {micro}g/mL), C5a (1.45{+/-}1.09 vs 0.38{+/-}0.48 {micro}g/mL) In contrast, no differences were found in serum complement levels were during the menstrual cycle. Complement concentrations were on average 308-fold (median= 84) lower in CM than in S, except for C3b/iC3b which was only 5 to 7.5-fold lower in CM, and C2 which was higher in CM at the luteal and follicular phases. Midcycle cervical mucus was capable of inducing complement-mediated hemolysis at about 1/3 the potency of serum. ConclusionCervical mucus contains detectable and functional levels of complement proteins. These normative values can provide a foundation for future studies on immune mechanisms in the FRT.

immunology↗

Revolutionizing male contraception: Personal lubricants as a novel way to deliver the Human Contraception Antibody

Study QuestionCan personal lubricants effectively deliver the sperm-agglutinating Human Contraception Antibody (HCA) to achieve on-demand male contraception? Summary AnswerThis study demonstrates that several water-based lubricants can effectively deliver bioactive HCA, and that a dimethicone-containing silicone lubricant can be modified into a stable emulsion suitable for antibody delivery. What Is Known AlreadyThe HCA-based vaginal film ZB-06 was shown to be safe and effective in a Phase I clinical trial for female contraception. Male contraceptive options remain limited. Using sexual lubricants as a delivery platform for HCA represents a novel and practical approach to male contraception. Study Design, Size, DurationWe tested the stability of HCA for up to two years in a variety of commercially available sexual lubricants, and its delivery from a penile device using a simulated intercourse model. Participants/Materials, Setting, MethodsFourteen commercial lubricants were initially screened for impact on sperm motility and viability, miscibility with HCA solution, and preservation of HCA activity (sperm agglutination test). From these, three water-based and one silicone-based lubricant were selected for further study. The silicone-based product was engineered into a novel emulsion (KY-DE) by incorporating 6% w/w PEG-10 dimethicone and 0.005% v/v TWEEN-20 for HCA integration. Formulations were tested for HCA functional stability and contraceptive efficacy over time using kinetic sperm agglutination assays and a capillary tube sperm penetration test. A novel simulated intercourse model was developed using a 3D-printed penile device and a vaginal analog (Fleshlight(R)). HCA-lube was applied to the "penis", and concentrations of HCA delivered to the "vagina" during intercourse were measured by ELISA and sperm agglutination assay. Safety evaluations were conducted using a vaginal tissue model (EpiVaginal, VEC-100-FT). Viability (MTT assay), tight junction integrity (TEER), and cytokine release were assessed after application of HCA-lube. Main Results and the Role of ChanceAll selected lubricants were nontoxic and did not affect HCAs ability to agglutinate sperm. In the capillary tube sperm penetration assay, HCA-formulated lubricants significantly impaired sperm penetration; few motile sperm penetrated past a depth of 1 cm after 90 minutes in the HCA-lubricants vs >80_in most of the untreated lubricants. Importantly, the simulated intercourse assay confirmed successful delivery of HCA to the vagina. Water-based lubricants delivered an average of 24 {+/-} 8.4 {micro}g/mL of HCA, the commercial silicone lubricant 11 {+/-} 5.2 {micro}g/mL, and the KY-DE emulsion 27.4 {+/-} 22.4 {micro}g/mL. Futhermore, the formulations did not compromise tissue integrity or viability, or induce significant inflammatory responses. Large Scale DataNot applicable. Limitations, Reasons for CautionWhile these in vitro results support the feasibility of using lubricants as HCA delivery vehicles, translation into clinical application requires further validation and clinical trials. Wider Implications of the FindingsThis work presents a new direction in male contraceptive development, leveraging the widespread use of personal lubricants to introduce antibody-based, reversible, on-demand contraception. Engineering a silicone-based lubricant that retains HCA activity under varied conditions and ensures higher mucosal delivery could further advance this approach. Study Funding/Competing Interest(s)This work was supported by a Sokol Grant from the Male Contraceptive Initiative, a Sexual Medicine Grant from Boston University Chobanian & Avedisian School of Medicine, and grant P50HD096957 from the National Institutes of Health. Kevin Whaley (ZabBio) intends to commercialize HCA for contraception. None of the other authors have competing interests.

bioengineering↗